R1 Resection in Gastrointestinal Stromal Tumors Is Not Worse Than R0
Menée à partir de données portant sur 908 patients atteints d'une tumeur stromale gastro-intestinale de stade localisé et inclus dans un essai de phase III évaluant un traitement adjuvant par imatinib (âge médian : 59 ans ; durée médiane de suivi : 9,1 ans), cette étude internationale évalue la survie globale des patients en fonction de la qualité de la résection chirurgicale
Gastrointestinal stromal tumors (GISTs) are malignant tumors arising from interstitial cells of cajal that can be located in any part of the digestive system. Their most common sites are the stomach and small intestine. Surgery either upfront or after preoperative treatment with tyrosine kinase inhibitors (TKIs) is still the most important treatment modality in GIST. In this issue of JAMA Surgery, Gronchi et al evaluate the association of microscopic radicality with patient outcomes. They use long-term data from a randomized clinical trial in which patients received TKI for 2 years or no adjuvant treatment after surgery to examine the association of R1 resection (no free margins) with recurrence and survival.
JAMA Surgery , commentaire, 2019